Apretude is long-acting cabotegravir used to reduce the chance of acquiring HIV-1 through sex. It is for people who do not have HIV. A healthcare professional gives the injection into a gluteal muscle. It can reduce the burden of taking a daily pill, but it replaces that routine with scheduled injections and HIV testing. It does not prevent other sexually transmitted infections or pregnancy. Choosing it means planning both the first visits and what to do if travel, insurance or illness disrupts a later appointment.
The US indication includes adults and adolescents who weigh at least 35 kg and are at risk of sexually acquired HIV. A clinician must confirm HIV-negative status and assess recent exposure and symptoms of acute HIV. Fever, rash, sore throat or swollen glands after a possible exposure need assessment even if a rapid test is negative. Apretude is not an adequate HIV treatment regimen. Relevant allergies, liver disease, pregnancy or breastfeeding, mental-health history and interacting medicines affect the discussion.
Discuss exposure, previous PrEP, adherence, injection preferences and ability to return. If possible HIV exposure occurred within the last 72 hours, seek urgent PEP assessment instead of waiting for a routine PrEP visit.
The plan includes an HIV antigen/antibody test and HIV RNA testing before injections. A negative antigen/antibody result requires RNA confirmation, even when the RNA result returns after an injection. Unclear or discordant results require clinical review before proceeding.
An oral cabotegravir lead-in may be offered to assess tolerability; it is optional. The first two injections are one month apart, followed by an injection every two months. Your team sets the target dates and explains the permitted appointment window.
Agree on STI screening, symptom contact, reminders and an alternative PrEP plan if injections stop. Bring up anticipated travel before a dose becomes overdue.